Small Cell Lung Cancer Clinical Trials 2018

At least 1 prior regimen must have contained a platinum salt adjuvant therapy will constitute a prior treatment.

Small cell lung cancer clinical trials 2018.

The efficacy and safety. All trials on the list are supported by nci. Clinical trials look at new ways to prevent detect or treat disease. Histologic or cytologic confirmed diagnosis of small cell lung cancer either limited or extensive disease at initial presentation is allowed.

Nci s basic information about clinical trials explains the types and phases of trials and how they are carried out. A phase 2 randomized clinical trial jama oncol. Listing a study does not mean it has been evaluated by the u s. The next section in this guide is latest research.

Clinical activity of immunotherapies has been observed in patients with refractory or metastatic small cell lung cancer 8 12. The clinical trials on this list are for small cell lung cancer treatment. Treatment patterns in advanced small cell lung cancer sclc the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. It explains areas of scientific research currently going on for small cell lung cancer.

In this commentary we review the timeline of clinical trials and regulatory actions of approved immune checkpoint inhibitors for small cell lung cancer discuss challenges faced by regulatory agencies and highlight paradoxical lessons that emerge. N engl j med. In a large clinical trial treatment with the immunotherapy drug atezolizumab tecentriq combined with a standard chemotherapy regimen increased survival in patients with this highly aggressive form of lung cancer. In addition this website offers free access to a video based educational program about cancer clinical trials located outside of this guide.

First line atezolizumab plus chemotherapy in extensive stage small cell lung cancer. However a phase 2 single group study of maintenance pembrolizumab and. Accelerated approvals may fail to expedite drugs to market in this setting and further research on overall survival benefit is needed to prove. Epub 2018 sep 25.

Osimertinib is standard of care therapy for previously untreated epidermal growth factor receptor egfr mutation positive advanced non small cell lung cancer nsclc. Use the menu to choose a different section to read in this guide. For the first time in more than two decades a treatment has been shown to improve how long patients with advanced small cell lung cancer sclc live.